Direct oral anticoagulants (DOACs) are now an option in the prevention and treatment of venous thromboembolic events (VTE) in patients with active cancer. Pharmacokinetics of DOACs are largely influenced by efflux transporters derived from …

2013年7月1日 · Several multitargeted vascular endothelial growth factor receptor (VEGFR) tyrosine-kinase inhibitors (TKI) agents have been approved including sunitinib, sorafenib, pazopanib, vandetanib and axitinib.

2023年5月31日 · We examined the incidence of VTE, a common adverse event (AE) among pts with lung cancer, for those receiving ami monotherapy, laz monotherapy, and ami+laz to investigate if there is elevated risk and understand potential predisposing risk factors.

2021年7月21日 · The current study showed that use of concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI) and therapeutic anticoagulation was associated with an increased risk of composite bleeding events, although at comparable rates between patients treated with VEGF TKI plus direct oral anticoagulant (DOAC) versus VEGF...

2025年3月1日 · Management of acute VTE on therapy (including TKI or amivantamab) in lung cancer follows established guidelines such as those from ASCO (Key et al., 2023); initial 6 months of anticoagulation with LMWH, edoxaban, rivaroxaban, or apixaban is strongly recommended, while anticoagulation beyond 6 months is offered to selected patients; generally ...

2023年12月19日 · 对于肺癌，酪氨酸激酶抑制剂（tki）基因突变、手术和ici治疗是近年来最值得关注的vte发生风险因素。在所有类型的tki基因突变中，alk重排与nsclc ...

2011年8月3日 · Venous and arterial thromboembolism events (VTEs and ATEs) are a major cause of death in cancer patients. The importance of cancer-associated thrombosis comes from the fact that it is exceedingly common in patients with cancer. One-fifth of all VTE events occur in cancer patients and the ones who develop VTE may experience serious consequences .

2024年11月17日 · 本研究首次通过全基因组关联分析（GWAS），探索了与ALK、ROS1融合阳性NSCLC患者VTE和ATE相关的临床人口统计学因素及胚系遗传因素。 该研究为一项前瞻性队列研究，纳入2014至2023年在多伦多玛嘉烈公主癌症研究中心接受治疗的150例ALK融合阳性患者及32例ROS1融合阳性NSCLC患者，从患者的外周全血标本中获取胚系DNA，同时收集患者临床人口统计学、治疗和结果数据。 将ATE和VTE作为时变协变量，经Cox回归评估VTE或ATE对患者 …

5 天之前 · 拉泽替尼是一种第三代egfr酪氨酸激酶抑制剂（tki），具有高选择性和脑渗透性，可同时抑制egfr敏感突变（如ex19del、l858r）及t790m耐药突变，且对野生型egfr影响较小，降低了传统egfr-tki的皮肤毒性风险。

Acute complications, such as venous thromboembolism (VTE) and central airway obstruction, are common in advanced severe lung cancer and are associated with decreased performance status. VTE, which includes pulmonary embolism, deep-vein thrombosis, and migratory thrombophlebitis, is a common cancer-associated complication .